Summary

U.S. Organ-on-a-Chip Market Summary

The U.S. organ-on-a-chip market size was estimated at USD 71.7 million in 2024 and is projected to reach USD 940.4 million by 2033, growing at a CAGR of 33.14% from 2025 to 2033. This growth is driven by increasing demand for more predictive preclinical testing models, a shift from animal testing, and rapid advancements in microfluidics, tissue engineering, and personalized medicine.

As pharmaceutical companies, biotech firms, and research institutions seek more accurate, ethical, and cost-effective ways to study human physiology and disease, organ-on-a-chip technologies are gaining traction as a transformative solution across the biomedical landscape.

Advancements in Microfluidics & Tissue Engineering

Advancements in microfluidics and tissue engineering have become a foundational driver of growth in the U.S. organ-on-a-chip industry. Microfluidic technologies enable precise control over the flow of nutrients, drugs, and mechanical stimuli at a microscale, closely mimicking the dynamic conditions of the human body. Tissue engineering complements this by enabling the creation of 3D cellular structures using human-derived cells, which can be designed to functionally resemble specific organs like the liver, lung, heart, or gut. These innovations have significantly improved the physiological relevance of preclinical testing, offering researchers more predictive and ethically responsible tools for studying disease and drug response.

The integration of stem cell technology, particularly induced pluripotent stem cells (iPSCs), further enhances the value of OOC platforms by allowing the development of patient-specific models. These personalized chips can reflect genetic variations and disease phenotypes unique to individuals, supporting precision medicine approaches. Moreover, recent innovations have allowed multiple organ systems to be connected on a single chip, enabling researchers to study how drugs or diseases affect the body rather than in isolation. This convergence of engineering and biology fuels sustained demand across the pharmaceutical, biotech, and academic research.

U.S. Organ-on-a-Chip Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the U.S. organ-on-a-chip market report based on the product & service, application, and end-use:

• Product & Service Outlook (Revenue, USD Million, 2021 - 2033)
• Products
o Instrument
o Devices
o Liver-on-a-Chip
o Lung-on-a-Chip
o Intestine-on-a-Chip
o Kidney-on-a-Chip
o Heart-on-a-Chip
o Others
• Services
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Drug Discovery
• Toxicology Research
• Others
• End-use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Others

ページTOPに戻る

Table of Contents

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.1.1. Product & Service Segment
1.1.2. Application Segment
1.1.3. End Use Segment
1.2. Estimates and Forecast Timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Primary Research
1.5. Information or Data Analysis:
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objective
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Advancements in microfluidics & tissue engineering
3.2.1.2. Increasing demand for disease modeling technologies
3.2.2. Market Restraint Analysis
3.2.2.1. Technical challenges and complexities associated with organ-on-a-chip technique
3.2.2.2. Regulatory hurdles in organ-on-a-chip method
3.3. Industry Analysis Tools
3.3.1. Porter’s Five Forces Analysis
3.3.2. PESTEL Analysis
Chapter 4. Product & Service Group Business Analysis
4.1. Product & Service Segment Dashboard
4.2. U.S. Organ-on-a-Chip Market Product & Service Movement Analysis
4.3. U.S. Organ-on-a-Chip Market Size & Trend Analysis, by Product & Service, 2021 to 2033 (USD Million)
4.4. Products
4.4.1. Products market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.2. Instruments
4.4.2.1. Instruments market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3. U.S. Organ-on-a-Chip Devices
4.4.3.1. Organ-on-a-chip devices market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3.2. Liver-on-a-Chip
4.4.3.2.1. Liver-on-a-chip market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3.3. Lung-on-a-Chip
4.4.3.3.1. Lung-on-a-chip market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3.4. Intestine-on-a-Chip
4.4.3.4.1. Intestine-on-a-chip market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3.5. Kidney-on-a-Chip
4.4.3.5.1. Kidney-on-a-chip market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3.6. Heart-on-a-Chip
4.4.3.6.1. Heart-on-a-chip market estimates and forecasts, 2021 - 2033 (USD Million)
4.4.3.7. Others
4.4.3.7.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
4.5. Services
4.5.1. Services market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 5. Application Group Business Analysis
5.1. Application Segment Dashboard
5.2. U.S. Organ-on-a-Chip Market Application Movement Analysis
5.3. U.S. Organ-on-a-Chip Market Size & Trend Analysis, by Application, 2021 to 2033 (USD Million)
5.4. Drug Discovery
5.4.1. Drug discovery market estimates and forecasts, 2021 - 2033 (USD Million)
5.5. Toxicology Research
5.5.1. Toxicology research market estimates and forecasts, 2021 - 2033 (USD Million)
5.6. Others
5.6.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 6. End Use Business Analysis
6.1. End Use Segment Dashboard
6.2. U.S. Organ-on-a-Chip Market End Use Movement Analysis
6.3. U.S. Organ-on-a-Chip Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
6.4. Pharmaceutical & Biotechnology Companies
6.4.1. Pharmaceutical & biotechnology companies market estimates and forecasts, 2021 - 2033 (USD Million)
6.5. Academic & Research Institute
6.5.1. Academic & research institute market estimates and forecasts, 2021 - 2033 (USD Million)
6.6. Others
6.6.1. Others market estimates and forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Company Categorization
7.2. Strategy Mapping
7.3. Company Market Position Analysis, 2024
7.4. Company Profiles/Listing
7.4.1. Emulate, Inc.
7.4.1.1. Overview
7.4.1.2. Financial Performance
7.4.1.3. Product Benchmarking
7.4.1.4. Strategic Initiatives
7.4.2. MIMETAS B.V.
7.4.2.1. Overview
7.4.2.2. Financial Performance
7.4.2.3. Product Benchmarking
7.4.2.4. Strategic Initiatives
7.4.3. Valo Health
7.4.3.1. Overview
7.4.3.2. Financial Performance
7.4.3.3. Product Benchmarking
7.4.3.4. Strategic Initiatives
7.4.4. Quris Technologies LTD. (Nortis, Inc.)
7.4.4.1. Overview
7.4.4.2. Financial Performance
7.4.4.3. Product Benchmarking
7.4.4.4. Strategic Initiatives
7.4.5. AxoSim
7.4.5.1. Overview
7.4.5.2. Financial Performance
7.4.5.3. Product Benchmarking
7.4.5.4. Strategic Initiatives
7.4.6. BICO - THE BIO CONVERGENCE COMPANY
7.4.6.1. Overview
7.4.6.2. Financial Performance
7.4.6.3. Product Benchmarking
7.4.6.4. Strategic Initiatives
7.4.7. CN Bio Innovations Ltd
7.4.7.1. Overview
7.4.7.2. Financial Performance
7.4.7.3. Product Benchmarking
7.4.7.4. Strategic Initiatives
7.4.8. The Charles Stark Draper Laboratory, Inc.
7.4.8.1. Overview
7.4.8.2. Financial Performance
7.4.8.3. Product Benchmarking
7.4.8.4. Strategic Initiatives
7.4.9. SynVivo, Inc.
7.4.9.1. Overview
7.4.9.2. Financial Performance
7.4.9.3. Product Benchmarking
7.4.9.4. Strategic Initiatives
7.4.10. AlveoliX AG
7.4.10.1. Overview
7.4.10.2. Financial Performance
7.4.10.3. Product Benchmarking
7.4.10.4. Strategic Initiatives